Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GSK 4001785A

Next Previous
Drug Profile

GSK 4001785A

Alternative Names: altSonflex1-2-3 vaccine; GSK-4001785A; Shigella vaccine - GlaxoSmithKline Biologicals

Latest Information Update: 12 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline Biologicals
  • Class Bacterial vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Shigella infections

Most Recent Events

  • 06 Jan 2026 GSK plans the phase II H06_04TP trial in Shigella infections (Prevention, In children) in Africa (IM) (NCT07320716)
  • 21 Oct 2025 GlaxoSmithKline completes phase-II clinical trials in Shigella infections (Prevention, In infants) in Kenya (IM) (NCT06663436)
  • 24 Jun 2025 GlaxoSmithKline completes a phase I/II clinical trials in Shigella infections (Prevention, In infants, In children, In adults) in Belgium and Kenya (IM) (EudraCT2021-000891-12) (NCT05073003)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top